Related references
Note: Only part of the references are listed.Salicylates are interference compounds in TR-FRET assays
Ronan P. Hanley et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2016)
Immunotherapy of cancer: from monoclonal to oligoclonal cocktails of anti-cancer antibodies: IUPHAR Review 18
Silvia Carvalho et al.
BRITISH JOURNAL OF PHARMACOLOGY (2016)
PD-1 immune checkpoint blockade reduces pathology and improves memory in mouse models of Alzheimer's disease
Kuti Baruch et al.
NATURE MEDICINE (2016)
Blocking of the PD-1/PD-L1 Interaction by a D-Peptide Antagonist for Cancer Immunotherapy
Hao-Nan Chang et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2015)
Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging
Roy L. Maute et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Structure of the Complex of Human Programmed Death 1, PD-1, and Its Ligand PD-L1
Krzysztof M. Zak et al.
STRUCTURE (2015)
Programmed Death-1: Therapeutic Success after More than 100 Years of Cancer Immunotherapy
Alexander Doemling et al.
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION (2014)
PD-1 and its ligands in tolerance and immunity
Mary E. Keir et al.
ANNUAL REVIEW OF IMMUNOLOGY (2008)
PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression
Cheryl L. Day et al.
NATURE (2006)
Share Paper
